Comparative Pharmacology
Head-to-head clinical analysis: KANAMYCIN versus LOTEPREDNOL ETABONATE AND TOBRAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KANAMYCIN versus LOTEPREDNOL ETABONATE AND TOBRAMYCIN.
KANAMYCIN vs LOTEPREDNOL ETABONATE AND TOBRAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis.
Loteprednol etabonate is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
15 mg/kg/day IM or IV in divided doses every 12 hours. Maximum daily dose: 1.5 g.
1-2 drops into affected eye(s) every 4-6 hours; in severe cases, may be given every 1-2 hours initially.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in patients with normal renal function (creatinine clearance >80 mL/min). In anuria, half-life may extend to 50-100 hours, necessitating dose adjustment based on renal function.
Clinical Note
moderateKanamycin + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Kanamycin."
Clinical Note
moderateKanamycin + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Kanamycin."
Clinical Note
moderateKanamycin + Deslanoside
"The serum concentration of Deslanoside can be decreased when it is combined with Kanamycin."
Clinical Note
moderateKanamycin + Acetyldigitoxin
Loteprednol etabonate: ~2.8 hours (ocular); Tobramycin: ~2-3 hours (systemic, prolonged in renal impairment)
Primarily renal excretion via glomerular filtration; approximately 80-90% of administered dose is excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<1%).
Loteprednol etabonate: 75% renal, 20% fecal; Tobramycin: >90% renal as unchanged drug via glomerular filtration
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic
"The serum concentration of Acetyldigitoxin can be decreased when it is combined with Kanamycin."